Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $50.6 million.

  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) rose 597.83% to $50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year increase of 597.83%. This contributed to the annual value of $47.5 million for FY2024, which is 1623.44% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Shares Outstanding (Weighted Average) of $50.6 million as of Q3 2025, which was up 597.83% from $49.7 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $50.6 million during Q3 2025, and its lowest value of $30.1 million during Q1 2021.
  • For the 5-year period, Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $39.5 million, with its median value being $38.1 million (2023).
  • In the last 5 years, Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 395.68% in 2022 and then surged by 2455.78% in 2024.
  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $30.3 million in 2021, then grew by 11.6% to $33.8 million in 2022, then increased by 20.82% to $40.9 million in 2023, then grew by 16.23% to $47.5 million in 2024, then increased by 6.56% to $50.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $50.6 million in Q3 2025, compared to $49.7 million in Q2 2025 and $48.9 million in Q1 2025.